CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Federzoni, Elena A ^a,b   Humbert, Magali ^a   Torbett, Bruce E ^b   Behre, Gerhard ^c   Fey, Martin F ^a,d   Tschan, Mario P ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; HEXOKINASE; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; HUMAN; METABOLISM; NEUTROPHIL; PATHOLOGY; TUMOR CELL LINE;

CCAAT-ENHANCER-BINDING PROTEINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HEXOKINASE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LEUKEMIA, MYELOID, ACUTE; NEUTROPHILS;

EID: 84897598302     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04261     Document Type: Article

References (29)

1. Radomska, H. S. et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol. Cell. Biol. 18, 4301-4314 (1998). (Pubitemid 28287953)
2. Zhang, D. E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94, 569-574 (1997).
3. Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89-101 (2003). (Pubitemid 37328876)
4. Zeisig, B. B., Kulasekararaj, A. G., Mufti, G. J. & So, C. W. E. SnapShot: Acute myeloid leukemia. Cancer Cell 22, 698-698.e1 (2012).
5. Paz-Priel, I. & Friedman, A. C/EBPa dysregulation in AML and ALL. Crit Rev Oncog 16, 93-102 (2011).
6. Pabst, T. & Mueller, B. U. Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia. Clin Cancer Res 15, 5303-5307 (2009).
7. Gombart, A. F. et al. Mutations in the Gene Encoding the Transcription Factor CCAAT/Enhancer Binding Protein A in Myelodysplastic Syndromes and Acute Myeloid Leukemias. Blood 99, 1332-1340 (2002). (Pubitemid 34547089)
8. Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F. & Falini, B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev. 27, 13-22 (2013).
9. Figueroa, M. E. et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114, 3448-3458 (2009).
10. Federzoni, E. A. et al. PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells. Blood 119, 4963-4970 (2012).
11. Humbert, M. et al. Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leuk. Res. 35, 909-913 (2011).
12. Rijksen, G, S. G., Rijksen, G., Staal, G. E., Beks, P. J. et al. Compartmentation of hexokinase in human blood cells. Characterization of soluble and particulate enzymes. Biochim. Biophys. Acta 719, 431-7 (1982). (Pubitemid 13191703)
13. McConnell, B. B. & Yang, V. W. Mammalian Krüppel-like factors in health and diseases. Physiol. Rev. 90, 1337-1381 (2010).
14. Diakiw, S. M. et al. The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. Leuk. Res. 36, 110-116 (2012).
15. Pulikkan, J. A. et al. C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 116, 5638-5649 (2010).
16. Taskesen, E. et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AMLpatients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117, 2469-2475 (2011).
17. D'Alo', F. et al. The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood 102, 3163-3171 (2003).
18. Rosenbauer, F. & Tenen, D. G. Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7, 105-117 (2007). (Pubitemid 46174858)
19. Nerlov, C. C/EBPα mutations in acute myeloid leukaemias. Nature Reviews Cancer 4, 394-400 (2004). (Pubitemid 38579485)
20. Schlenk, R. F. et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358, 1909-1918 (2008). (Pubitemid 351620111)
21. Yang, J. et al. Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha. J. Biol. Chem. 280, 38689-38699 (2005). (Pubitemid 43853772)
22. Bereshchenko, O. et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell 16, 390-400 (2009).
23. Kirstetter, P. et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell 13, 299-310 (2008). (Pubitemid 351446194)
24. Dong, J.-T. & Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell. Mol. Life Sci. 66, 2691-2706 (2009).
25. Karp, J. E. & Rassool, F. V. KLFs and ATRA-induced differentiation: New pathways for exploitation. Leukemia Research 35, 846-847 (2011).
26. Diakiw, S. M. et al. Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. Br. J. Haematol. 161, 884-888 (2013).
27. Chen, C. et al. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene 330, 133-142 (2004). (Pubitemid 38490426)
28. López-Rodríguez, C., Botella, L. & Corbí, A. L. CCAAT-enhancer-binding proteins (C/EBP) regulate the tissue specific activity of the CD11c integrin gene promoter through functional interactions with Sp1 proteins. J. Biol. Chem. 272, 29120-29126 (1997). (Pubitemid 27498201)
29. Kaeser, M. D. & Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 99, 95-100 (2002). (Pubitemid 34060322)